Autosomal dominant spastic ataxia type 1

Autosomal dominant spastic ataxia type 1 (SPAX1), also known as spastic ataxia 1, is a rare hereditary neurological disorder characterized by the combination of cerebellar ataxia and spastic paraplegia. The condition primarily affects the nervous system, specifically the cerebellum (the part of the brain responsible for coordination) and the upper motor neuron pathways in the spinal cord. SPAX1 is caused by mutations in the VAMP1 gene (also referred to in some classifications by associated loci), though the precise genetic basis has been refined over time. Affected individuals typically develop progressive difficulty with walking and coordination, with both cerebellar dysfunction (causing unsteadiness, impaired balance, and incoordination) and spasticity (stiffness) in the lower limbs. Key clinical features include progressive gait ataxia, lower limb spasticity, dysarthria (slurred speech), and hyperreflexia. Some patients may also experience upper limb involvement, eye movement abnormalities such as nystagmus, and urinary urgency. The disease tends to manifest in adulthood, though the age of onset can vary among affected family members. The progression is generally slow but leads to increasing disability over time. There is currently no cure or disease-modifying treatment for autosomal dominant spastic ataxia type 1. Management is symptomatic and supportive, focusing on physical therapy to maintain mobility and reduce spasticity, occupational therapy, speech therapy for dysarthria, and medications such as baclofen or tizanidine to manage spasticity. Regular neurological follow-up is recommended to monitor disease progression and adjust supportive care accordingly.

Common questions about Autosomal dominant spastic ataxia type 1